Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FRMD4A antisense RNA 3 (FRMD4A-AS3) is presumed to be a long non-coding RNA (lncRNA) that is transcribed antisense to the FRMD4A gene. Antisense RNAs generally regulate their corresponding sense genes via mechanisms such as modulation of splicing, transcript stability, or translation. There is currently no literature or database evidence specifically describing the function, disease role, or therapeutic relevance of FRMD4A-AS3; the related FRMD4A antisense RNAs (e.g., FRMD4A-AS1, FRMD4A-AS2) have limited functional characterization, and no evidence was found that FRMD4A-AS3 is a recognized therapeutic target or biomarker. It does not encode a receptor, enzyme, or protein but likely represents a non-coding regulatory transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FRMD4A antisense RNA 3 (FRMD4A-AS3).